{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:27:24Z","timestamp":1793608044223,"version":"4.5.0"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vaccine.2026.129120","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:00:43Z","timestamp":1788472843000},"page":"129120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Incidence, risk factors, and association with vaccination of thrombocytopenia and immune thrombocytopenia (ITP): A scoping review"],"prefix":"10.1016","volume":"92","author":[{"given":"Matthew Z.","family":"Dudley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Rojo","family":"Villaescusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.vaccine.2026.129120_bb0005","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129120_bb0010","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3949\/ccjm.78gr.10005","article-title":"Immune thrombocytopenia: no longer \u2018idiopathic\u2019","volume":"78","author":"McCrae","year":"2011","journal-title":"Cleve Clin J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129120_bb0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/21548331.1997.11443569","article-title":"Clinical decisions in idiopathic thrombocytopenic Purpura","volume":"32","author":"George","year":"1997","journal-title":"Hosp Pract"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.hoc.2013.03.001","article-title":"Immune thrombocytopenia","volume":"27","author":"Kistangari","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129120_bb0025","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.vaccine.2026.129120_bb0030","unstructured":"Brighton Collaboration. [cited 2025 July 25, 2025]; Available from: https:\/\/brightoncollaboration.org\/."},{"issue":"15\u201316","key":"10.1016\/j.vaccine.2026.129120_bb0035","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.vaccine.2004.01.016","article-title":"The Brighton collaboration-enhancing vaccine safety","volume":"22","author":"Bonhoeffer","year":"2004","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2026.129120_bb0045","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1016\/j.vaccine.2007.02.067","article-title":"Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Wise","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129120_bb0050","author":"Law"},{"key":"10.1016\/j.vaccine.2026.129120_bb0055","author":"Law"},{"key":"10.1016\/j.vaccine.2026.129120_bb0060","series-title":"creating healthy and sustainable buildings: An assessment of health risk factors","author":"Dovjak","year":"2019"},{"key":"10.1016\/j.vaccine.2026.129120_bb0065","unstructured":"A Dictionary of Epidemiology. Fourth ed. 2000, New York, New York: Oxford University Press."},{"issue":"7","key":"10.1016\/j.vaccine.2026.129120_bb0070","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0075","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1542\/peds.2007-1129","article-title":"A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children","volume":"121","author":"Glanz","year":"2008","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129120_bb0080","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/13696998.2019.1669329","article-title":"Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis","volume":"23","author":"Weycker","year":"2020","journal-title":"J Med Econ"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0085","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/09537104.2019.1635687","article-title":"The incidence and clinical burden of immune thrombocytopenia in pediatric patients in the United States","volume":"31","author":"Shaw","year":"2020","journal-title":"Platelets"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0090","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1600-0609.1976.tb01142.x","article-title":"Thrombocytopenia in childhood: an evaluation of 433 patients","volume":"16","author":"Cohn","year":"1976","journal-title":"Scand J Haematol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129120_bb0095","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2796.1972.tb00096.x","article-title":"THROMBOCYTOPENIA","volume":"191","author":"B\u00f6ttiger","year":"1972","journal-title":"J Intern Med"},{"issue":"22","key":"10.1016\/j.vaccine.2026.129120_bb0100","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France","volume":"124","author":"Moulis","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0105","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00277-014-2220-z","article-title":"Immune thrombocytopenia: epidemiological and clinical features of 216 patients in northwestern Turkey","volume":"94","author":"Koylu","year":"2015","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vaccine.2022.11.031","article-title":"Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study","volume":"41","author":"Willame","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129120_bb0115","article-title":"Characterising the background incidence rates of adverse events of special interest for COVID-19 vaccines in eight countries: multinational network cohort study","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129120_bb0120","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1177\/000992280404300802","article-title":"Idiopathic thrombocytopenic Purpura: A 10-year natural history study at the Childrens Hospital of Alabama","volume":"43","author":"Watts","year":"2004","journal-title":"Clin Pediatr"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0125","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s12185-011-0791-1","article-title":"Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review","volume":"93","author":"Kurata","year":"2011","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129120_bb0130","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1046\/j.1365-2141.2003.04547.x","article-title":"Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients","volume":"122","author":"Neylon","year":"2003","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129120_bb0135","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1365-2141.2010.08176.x","article-title":"Epidemiology of paediatric immune thrombocytopenia in the general practice research database","volume":"149","author":"Yong","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129120_bb0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0609.2009.01247.x","article-title":"The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review","volume":"83","author":"Abrahamson","year":"2009","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129120_bb0145","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07615.x","article-title":"Epidemiology of immune thrombocytopenic purpura in the general practice research database","volume":"145","author":"Schoonen","year":"2009","journal-title":"Br J Haematol"},{"issue":"9078","key":"10.1016\/j.vaccine.2026.129120_bb0150","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(97)04143-3","article-title":"Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines","volume":"350","author":"Bolton-Maggs","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0155","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1055\/s-2001-15255","article-title":"Acute immune thrombocytopenia (ITP) in childhood: retrospective and prospective survey in Germany","volume":"27","author":"Sutor","year":"2001","journal-title":"Semin Thromb Hemost"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129120_bb0160","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/08880010050122816","article-title":"Immune thrombocytopenic purpura in childhood in Norway: a prospective, population-based registration","volume":"17","author":"Zeller","year":"2000","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0165","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.V94.3.909.415k02_909_913","article-title":"The incidence of idiopathic thrombocytopenic purpura in adults increases with age","volume":"94","author":"Frederiksen","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129120_bb0170","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1651-2227.2005.tb01887.x","article-title":"Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease","volume":"94","author":"Zeller","year":"2005","journal-title":"Acta Paediatr"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0175","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40264-020-01031-1","article-title":"Incidence rates of autoimmune diseases in European healthcare databases: A contribution of the ADVANCE project","volume":"44","author":"Willame","year":"2021","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0180","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/tropej\/36.1.10","article-title":"Childhood idiopathic thrombocytopenic purpura: report of 60 cases from Kuwait","volume":"36","author":"Zaki","year":"1990","journal-title":"J Trop Pediatr"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0185","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/adc.71.3.251","article-title":"Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Paediatric haematology forum of the British Society for Haematology","volume":"71","author":"Lilleyman","year":"1994","journal-title":"Arch Dis Child"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129120_bb0190","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1111\/jog.14890","article-title":"A meta-analysis of neonatal outcomes in pregnant women with immune thrombocytopenic purpura","volume":"47","author":"Luo","year":"2021","journal-title":"J Obstet Gynaecol Res"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129120_bb0195","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/ajh.24829","article-title":"Platelet counts in women with normal pregnancies: A systematic review","volume":"92","author":"Reese","year":"2017","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129120_bb0200","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MBC.0b013e32835fad03","article-title":"May-Hegglin anomaly and pregnancy: a systematic review","volume":"24","author":"Hussein","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129120_bb0205","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12758","article-title":"Associations between FCGR polymorphisms and immune thrombocytopenia: a meta-analysis","volume":"89","author":"Li","year":"2019","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2026.129120_bb0210","doi-asserted-by":"crossref","first-page":"766","DOI":"10.12659\/MSM.895558","article-title":"Common polymorphisms in IL-27 genes may contribute to risk of various human diseases in Asian populations: A Meta-analysis","volume":"22","author":"Zhang","year":"2016","journal-title":"Med Sci Monit"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129120_bb0215","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1177\/0961203315624557","article-title":"Association between interferon-\u03b3 +874 T\/A polymorphism and susceptibility to autoimmune diseases: a meta-analysis","volume":"25","author":"Lee","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.vaccine.2026.129120_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156538","article-title":"TNF\u03b1-308G>A polymorphism and susceptibility to immune thrombocytopenia Purpura (ITP): evidence from a systematic review and Meta-analysis","volume":"177","author":"Shams","year":"2024","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129120_bb0225","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27569","article-title":"Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: A critical review of the literature","volume":"66","author":"Neunert","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129120_bb0230","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00134-020-06031-4","article-title":"Platelets and extra-corporeal membrane oxygenation in adult patients: a systematic review and meta-analysis","volume":"46","author":"Jiritano","year":"2020","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0235","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/aas.13699","article-title":"Thrombocytopenia in intensive care unit patients: A scoping review","volume":"65","author":"Jonsson","year":"2021","journal-title":"Acta Anaesthesiol Scand"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0240","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17474086.2017.1271319","article-title":"Thrombocytopenia and infections","volume":"10","author":"Franchini","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0245","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/bjh.16655","article-title":"The proportion of patients with thrombocytopenia in three human-susceptible coronavirus infections: a systematic review and meta-analysis","volume":"189","author":"Zhou","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0250","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1186\/s12879-020-05303-0","article-title":"Severe fever with thrombocytopenia syndrome: a systematic review and meta-analysis of epidemiology, clinical signs, routine laboratory diagnosis, risk factors, and outcomes","volume":"20","author":"He","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129120_bb0255","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4103\/ijo.IJO_2232_20","article-title":"Ocular leishmaniasis - A systematic review","volume":"69","author":"Mignot","year":"2021","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0260","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12879-020-05046-y","article-title":"Prevalence and risk factors related to poor outcome of patients with severe Plasmodium vivax infection: a systematic review, meta-analysis, and analysis of case reports","volume":"20","author":"Kotepui","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0265","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40249-018-0392-9","article-title":"Severe thrombocytopaenia in patients with vivax malaria compared to falciparum malaria: a systematic review and meta-analysis","volume":"7","author":"Naing","year":"2018","journal-title":"Infect Dis Poverty"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129120_bb0270","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12519-022-00650-1","article-title":"Safety and clinical efficacy of linezolid in children: a systematic review and meta-analysis","volume":"19","author":"Shi","year":"2023","journal-title":"World J Pediatr"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129120_bb0275","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00228-023-03542-z","article-title":"Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis","volume":"79","author":"Zhang","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129120_bb0280","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ehjcvp\/pvu008","article-title":"Risk of thrombocytopenia with glycoprotein IIb\/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials","volume":"1","author":"Wessler","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0285","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/jth.12052","article-title":"A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia","volume":"11","author":"Arnold","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vaccine.2026.129120_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1375615","article-title":"Risk of secondary immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis","volume":"15","author":"Sun","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.vaccine.2026.129120_bb0295","first-page":"232","article-title":"Watch the walnuts: severe immune thrombocytopenia after consumption of English walnuts","volume":"37","author":"Vermeer","year":"2012","journal-title":"Ned Tijdschr Klin Chem Labgeneeskd"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129120_bb0300","first-page":"273","article-title":"Idiopathic thrombocytopenic purpura (ITP) - new era for an old disease","volume":"57","author":"Onis\u00e2i","year":"2019","journal-title":"Rom J Intern Med"},{"issue":"26","key":"10.1016\/j.vaccine.2026.129120_bb0305","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1182\/blood-2009-01-129155","article-title":"The ITP syndrome: pathogenic and clinical diversity","volume":"113","author":"Cines","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129120_bb0310","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1586\/ehm.12.7","article-title":"Risk and prognosis of adult primary immune thrombocytopenia","volume":"5","author":"Frederiksen","year":"2012","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129120_bb0315","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/1024533032000158850","article-title":"Adult idiopathic thrombocytopenic purpura","volume":"8","author":"Mead","year":"2003","journal-title":"Hematology (Amsterdam)"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0320","doi-asserted-by":"crossref","first-page":"729","DOI":"10.26719\/2009.15.3.729","article-title":"Immune thrombocytopenia in children with reference to low-income countries","volume":"15","author":"Rehman","year":"2009","journal-title":"East Mediterr Health J"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0325","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/asheducation-2006.1.97","article-title":"Immune thrombocytopenic purpura of childhood","volume":"2006","author":"Nugent","year":"2006","journal-title":"Hematology (Amsterdam)"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129120_bb0330","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1542\/peds.2013-3320","article-title":"Incidence and consequences of neonatal alloimmune thrombocytopenia: a systematic review","volume":"133","author":"Kamphuis","year":"2014","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129120_bb0335","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0950-3536(98)80052-8","article-title":"Immune-mediated thrombocytopenias: basic and immunological aspects","volume":"11","author":"Porcelijn","year":"1998","journal-title":"Baillieres Clin Haematol"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129120_bb0340","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1080\/14767058.2020.1786527","article-title":"Thrombocytopaenia in pregnancy: the importance of differential diagnosis during the COVID-19 pandemic","volume":"35","author":"Zitiello","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129120_bb0345","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S1473-3099(20)30130-4","article-title":"The state of vaccine safety science: systematic reviews of the evidence","volume":"20","author":"Dudley","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0350","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.vaccine.2017.05.012","article-title":"Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination","volume":"36","author":"Perez-Vilar","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129120_bb0355","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1542\/peds.2011-1111","article-title":"The risk of immune thrombocytopenic purpura after vaccination in children and adolescents","volume":"129","author":"O\u2019Leary","year":"2012","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129120_bb0360","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4161\/hv.3.2.3878","article-title":"Post-licensure safety of the meningococcal group C conjugate vaccine","volume":"3","author":"Andrews","year":"2007","journal-title":"Hum Vaccin"},{"issue":"19","key":"10.1016\/j.vaccine.2026.129120_bb0365","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.vaccine.2011.06.009","article-title":"A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark","volume":"30","author":"Andrews","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129120_bb0370","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/sim.7536","article-title":"Investigating the assumptions of the self-controlled case series method","volume":"37","author":"Whitaker","year":"2018","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0375","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/sta4.166","article-title":"Bias and estimation under misspecification of the risk period in self-controlled case series studies","volume":"6","author":"Campos","year":"2017","journal-title":"Stat"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0380","doi-asserted-by":"crossref","first-page":"e687","DOI":"10.1542\/peds.2007-1578","article-title":"Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children","volume":"121","author":"France","year":"2008","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0385","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11530350-000000000-00000","article-title":"Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy","volume":"33","author":"Bertuola","year":"2010","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129120_bb0390","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1542\/peds.2014-1822","article-title":"Safety of measles-containing vaccines in 1-year-old children","volume":"135","author":"Klein","year":"2015","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129120_bb0395","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/j.vaccine.2006.10.054","article-title":"Vaccination associated thrombocytopenic purpura in children","volume":"25","author":"Rajantie","year":"2007","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129120_bb0400","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2165\/11537630-000000000-00000","article-title":"Temporal data mining for adverse events following immunization in nationwide Danish healthcare databases","volume":"33","author":"Svanstr\u00f6m","year":"2010","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0405","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/adc.84.3.227","article-title":"Idiopathic thrombocytopenic purpura and MMR vaccine","volume":"84","author":"Miller","year":"2001","journal-title":"Arch Dis Child"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129120_bb0410","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.4161\/hv.23601","article-title":"Vaccine administration and the development of immune thrombocytopenic purpura in children","volume":"9","author":"Cecinati","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0415","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-47486-x","article-title":"Thrombocytopenia and venous thromboembolic events after BNT162b2, CoronaVac, ChAdOx1 vaccines and SARS-CoV-2 infection: a self-controlled case series study","volume":"13","author":"Ab Rahman","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.129120_bb0420","article-title":"Thrombocytopenic, thromboembolic and haemorrhagic events following second dose with BNT162b2 and ChAdOx1: self-controlled case series analysis of the English national sentinel cohort","volume":"32","author":"Joy","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129120_bb0425","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"27","author":"Simpson","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0430","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1038\/s41467-022-32264-6","article-title":"Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"13","author":"Simpson","year":"2022","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129120_bb0435","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.17375","article-title":"Analysis of thromboembolic and thrombocytopenic events after the AZD1222, BNT162b2, and MRNA-1273 COVID-19 vaccines in 3 Nordic countries","volume":"5","author":"Dag Berild","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.129120_bb0440","article-title":"Risk of thrombocytopenia and thromboembolism after COVID-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study","volume":"374","author":"Hippisley-Cox","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129120_bb0445","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/M21-2452","article-title":"Association of AZD1222 and BNT162b2 COVID-19 vaccination with thromboembolic and thrombocytopenic events in frontline personnel: a retrospective cohort study","volume":"175","author":"Hviid","year":"2022","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0450","doi-asserted-by":"crossref","first-page":"7169","DOI":"10.1038\/s41467-022-34669-9","article-title":"Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in Catalonia, Spain","volume":"13","author":"Burn","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0455","article-title":"Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom","volume":"13","author":"Burn","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129120_bb0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003926","article-title":"Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: a population-based cohort study of 46 million adults in England","volume":"19","author":"Whiteley","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2026.129120_bb0465","article-title":"Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in England","volume":"13","author":"Andrews","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"32","key":"10.1016\/j.vaccine.2026.129120_bb0470","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1016\/j.vaccine.2023.06.014","article-title":"Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: two self-controlled studies in the U.S","volume":"41","author":"Shoaibi","year":"2023","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129120_bb0475","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S1473-3099(23)00207-4","article-title":"Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study","volume":"23","author":"Yamin","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129120_bb0480","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/ajh.26478","article-title":"COVID-19 vaccines and risks of hematological abnormalities: nested case-control and self-controlled case series study","volume":"97","author":"Sing","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0485","doi-asserted-by":"crossref","first-page":"16406","DOI":"10.1038\/s41598-022-20118-6","article-title":"Risk of thrombocytopenic, haemorrhagic and thromboembolic disorders following COVID-19 vaccination and positive test: a self-controlled case series analysis in Wales","volume":"12","author":"Torabi","year":"2022","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129120_bb0490","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.129120_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102154","article-title":"Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study","volume":"63","author":"Peng","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"52","key":"10.1016\/j.vaccine.2026.129120_bb0500","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.1016\/j.vaccine.2022.10.088","article-title":"A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan","volume":"40","author":"Takeuchi","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129120_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2023.100419","article-title":"Nationwide safety surveillance of COVID-19 mRNA vaccines following primary series and first booster vaccination in Singapore","volume":"15","author":"Dorajoo","year":"2023","journal-title":"Vaccine X"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129120_bb0510","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.26852","article-title":"Comparative risks of potential adverse events following COVID-19 mRNA vaccination among older US adults","volume":"6","author":"Harris","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0515","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/AOG.0000000000005241","article-title":"Medically attended acute adverse events in pregnant people after coronavirus disease 2019 (COVID-19) booster vaccination","volume":"142","author":"DeSilva","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"14","key":"10.1016\/j.vaccine.2026.129120_bb0520","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129120_bb0525","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/bloodadvances.2021006379","article-title":"COVID-19 vaccination in patients with immune thrombocytopenia","volume":"6","author":"Visser","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129120_bb0530","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/jth.15704","article-title":"Real-world, single-center experience of SARS-CoV-2 vaccination in immune thrombocytopenia","volume":"20","author":"Woolley","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0535","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/bjh.19212","article-title":"Safety and efficacy of SARS-CoV-2 vaccination in patients with immune thrombocytopenia: A two-Centre review","volume":"204","author":"Stefani","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.vaccine.2026.129120_bb0540","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/JBM.S396026","article-title":"Immune thrombocytopenia relapse in patients who received mRNA COVID-19 vaccines","volume":"14","author":"Qasim","year":"2023","journal-title":"J Blood Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0545","doi-asserted-by":"crossref","first-page":"e2023029","DOI":"10.4084\/MJHID.2023.029","article-title":"Immune thrombocytopenia onset and relapse during the COVID-19 pandemic. A monocenter study","volume":"15","author":"Auteri","year":"2023","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129120_bb0550","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1182\/blood.2021013411","article-title":"SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP","volume":"139","author":"Lee","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129120_bb0555","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/09537104.2022.2071856","article-title":"Exacerbation of immune thrombocytopenia following initial and booster vaccination with Pfizer-BioNTech COVID-19 vaccine","volume":"33","author":"Aharoni","year":"2022","journal-title":"Platelets"},{"key":"10.1016\/j.vaccine.2026.129120_bb0560","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.imlet.2023.11.007","article-title":"Platelet dropping, bleeding and new treatment requirements in ITP patients after inactivated COVID-19 vaccination","volume":"264","author":"Zhan","year":"2023","journal-title":"Immunol Lett"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129120_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10112674","article-title":"Impact of COVID-19 infection, vaccination, and serological response in immune thrombocytopenic purpura patients: A single-center global analysis","volume":"10","author":"Dainese","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129120_bb0570","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/jamainternmed.2021.8523","article-title":"Risk of immune thrombocytopenia after influenza vaccine","volume":"182","author":"Lafaurie","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129120_bb0575","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.4161\/21645515.2014.972149","article-title":"Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials","volume":"10","author":"Vaughn","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"25","key":"10.1016\/j.vaccine.2026.129120_bb0580","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1182\/blood-2012-05-431098","article-title":"A case-control study to assess the risk of immune thrombocytopenia associated with vaccines","volume":"120","author":"Grimaldi-Bensouda","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129120_bb0585","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00228-011-1184-3","article-title":"Drug-induced immune thrombocytopaenia: results from the Berlin case-control surveillance study","volume":"68","author":"Garbe","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129120_bb0590","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/AOG.0b013e3182831b83","article-title":"Maternal safety of trivalent inactivated influenza vaccine in pregnant women","volume":"121","author":"Nordin","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"39","key":"10.1016\/j.vaccine.2026.129120_bb0595","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1016\/j.vaccine.2014.07.017","article-title":"Monovalent H1N1 influenza vaccine safety in pregnant women, risks for acute adverse events","volume":"32","author":"Nordin","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129120_bb0600","doi-asserted-by":"crossref","unstructured":"Huang, W.T., et al., The reporting completeness of a passive safety surveillance system for pandemic (H1N1) 2009 vaccines: a capture-recapture analysis. Vaccine, 2012. 30(12): p. 2168\u201372.","DOI":"10.1016\/j.vaccine.2012.01.013"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129120_bb0605","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joim.12155","article-title":"Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects","volume":"275","author":"Grimaldi-Bensouda","year":"2014","journal-title":"J Intern Med"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129120_bb0610","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/imj.13005","article-title":"Adverse event monitoring of the human papillomavirus vaccines in Scotland","volume":"46","author":"Cameron","year":"2016","journal-title":"Intern Med J"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129120_bb0615","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.vaccine.2024.02.085","article-title":"Evaluation of the safety profile of the quadrivalent vaccine against human papillomavirus in the risk of developing autoimmune, neurological, and hematological diseases in adolescent women in Colombia","volume":"42","author":"Maldonado","year":"2024","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0620","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyae010","article-title":"Neurological and immunological adverse events after pneumococcal conjugate vaccine in children using national immunization programme registry data","volume":"53","author":"Kim","year":"2024","journal-title":"Int J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0625","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.52597","article-title":"Cardiovascular, neurological, and immunological adverse events and the 23-valent pneumococcal polysaccharide vaccine","volume":"7","author":"Yoon","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129120_bb0630","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.vaccine.2023.11.053","article-title":"Immune thrombocytopenic purpura and Guillain-Barr\u00e9 syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: the vaccine effectiveness, networking, and universal safety (VENUS) study","volume":"42","author":"Sato","year":"2024","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2026.129120_bb0635","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.vaccine.2013.03.040","article-title":"Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children","volume":"31","author":"Tseng","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129120_bb0640","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy100","article-title":"Pneumococcal conjugate vaccine safety in elderly adults","volume":"5","author":"Tseng","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129120_bb0645","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.vaccine.2020.01.090","article-title":"Assessment of pre-specified adverse events following varicella vaccine: a population-based self-controlled risk interval study","volume":"38","author":"Liu","year":"2020","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129120_bb0650","first-page":"681","article-title":"Severe autoimmune adverse events post herpes zoster vaccine: A case-control study of adverse events in a National Database","volume":"14","author":"Lai","year":"2015","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129120_bb0655","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1097\/MPH.0000000000000388","article-title":"A case of immune thrombocytopenic Purpura after rabies vaccination","volume":"37","author":"Fulbright","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129120_bb0660","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4103\/jgid.jgid_312_20","article-title":"Immune thrombocytopenia: a rare complication of rabies vaccine","volume":"13","author":"Bansal","year":"2021","journal-title":"J Global Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129120_bb0665","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41541-019-0152-2","article-title":"Febrile illness and bicytopenia within hours after tick-borne encephalitis booster vaccination","volume":"4","author":"B\u00fchler","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129120_bb0670","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.4161\/hv.24847","article-title":"Acute immune thrombocytopenic purpura as adverse reaction to oral polio vaccine (OPV)","volume":"9","author":"Jin","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"51","key":"10.1016\/j.vaccine.2026.129120_bb0675","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1016\/j.vaccine.2008.09.062","article-title":"Severe thrombocytopenia after hepatitis B vaccine in an infant from Turkey","volume":"26","author":"Polat","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129120_bb0680","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jpeds.2009.10.015","article-title":"Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management","volume":"156","author":"Mantadakis","year":"2010","journal-title":"J Pediatr"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:37:18Z","timestamp":1793605038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26009291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":135,"alternative-id":["S0264410X26009291"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129120","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence, risk factors, and association with vaccination of thrombocytopenia and immune thrombocytopenia (ITP): A scoping review","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"129120"}}